standard care + rotigotine at 4 mg/24h for 24 months. for kidney diseases

A treatment and a condition, followed through the public trial records. Not medical advice. How a status is set

Phase 2 trial. Mid-stage trial in people. As of 19 Nov 2026, from 1 registered trial.

Why this status

  1. 4 Mar 2024: Trial registered, NCT06291116
  2. 12 May 2026: Trial started, NCT06291116

The trials

NCT06291116: Safety of RotigotiNe in Patients With Autosomal Dominant Polycystic Kidney Disease

State
Under way
Phase
Phase 2
People
120 planned
Started
12 May 2026
Primary completion
1 Jul 2030
Arms
experimental
Results
None posted
  1. 4 Mar 2024: Trial registered
  2. 12 May 2026: Trial started

How the status changed

  1. 19 Nov 2026: First set: Phase 2 trial

About the treatment

Kind of treatment: Drug.

Registries searched: ClinicalTrials.gov, through 17 Nov 2026.